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Background: The BODE score (incorporating body mass index, airflow obstruction, dyspnea 
and exercise capacity) is used for the timing of listing for lung transplantation (LTx) in COPD, 
based on survival data from the original BODE cohort. This has limitations, because the original 
BODE cohort differs from COPD patients who are candidates for LTx and the BODE does not 
include parameters that may influence survival. Our goal was to assess whether parameters such 
as age, smoking status and diffusion indices significantly influence survival in the absence of 
LTx, independently of the BODE.
Methods: In the present cohort study, the BODE was prospectively assessed in COPD patients 
followed in a tertiary care hospital with an LTx program. The files of 469 consecutive patients 
were reviewed for parameters of interest (age, gender, smoking status and diffusing capacity 
of the lungs for carbon monoxide [DL,CO]) at the time of BODE assessment, as well as for 
survival status. Their influence on survival independent of the BODE score was assessed, as 
well as their ability to predict survival in patients aged less than 65 years.
Results: A Cox regression model showed that the BODE score, age and DL,CO were inde-
pendently related to survival (P-values ,0.001), as opposed to smoking status. Survival was 
better in patients aged less than 65 in the first (P=0.004), third (P=0.002) and fourth BODE 
quartiles (P=0.008). The difference did not reach significance in the second quartile (P=0.13). 
Median survival for patients aged less than 65 in the fourth BODE quartile was 55 months. 
According to a receiver operating characteristic curve analysis, the BODE score as well as 
FEV
1
 and DL,CO fared similarly in predicting survival status at 5 years in patients aged less 
than 65 years.
Conclusion: Age and DL,CO add to the BODE score to predict survival in COPD. Assessing 
survival using tools tested in cohorts of patients younger than 65 years is warranted for improv-
ing the listing of patients for LTx.
Keywords: age, DL, CO, BODE index, survival, COPD, smoking status, gender
Introduction
COPD is a common, preventable and treatable disease characterized by persistent 
respiratory symptoms and airflow limitation due to airway and alveolar abnormalities 
caused by exposure to noxious particles or gases.1 COPD is a major cause of mortality, 
being the fourth leading cause of death worldwide with more than 3 million annual 
deaths.2
Various tools have been developed to predict mortality in patients with COPD. In a 
clinical setting, these are mostly useful in the context of lung transplantation (LTx), 
for which COPD is the first indication.3 Indeed, it is recommended to list a patient 
for LTx if transplantation is expected to provide a survival advantage over optimal 
medical treatment.4 In COPD patients, FEV
1
 has been recognized as a determinant 
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of survival since Fletcher and Peto’s landmark study,5 later 
confirmed by other large studies including the Intermittent 
Positive Pressure Breathing (IPPB) trial, where FEV
1
 and 
age were the best predictors of mortality.6
More recently, other parameters such as dyspnea,7 the 
Six-Minute Walk Test distance8 and body mass index (BMI)9 
were shown to be independently associated with survival. 
This led to the development of multidimensional indices 
such as the BODE. The BODE is a 0–10 scale based on the 
BMI (B), the degree of airflow obstruction (O; assessed by 
FEV
1
), dyspnea (D; assessed by the mMRC dyspnea scale) 
and exercise capacity (E; assessed by the Six-Minute Walk 
Test distance). In their seminal paper, Celli et al showed 
that the BODE score was a better predictor of mortality 
than FEV
1
.10
The BODE is recommended as a criterion for both 
referral (BODE score =5–6) and listing (BODE score $7) 
of COPD patients for LTx.3,11 This recommendation of the 
International Society for Heart and Lung Transplantation 
(ISHLT) is based on the median survival of 37 months for 
patients with a BODE score $7 in the original publication 
of Celli et al.10 This is worse than the current expected 
6 years’ median survival after LTx.12 Lahzami et al compared 
the survival of their transplanted COPD patients with that 
of patients from the BODE cohort. This led them to state 
that using a BODE score $7 indeed conferred a survival 
advantage for LTx.13
The study by Lahzami et al13 and the recommendation by 
the ISHLT, however, have several shortcomings.14 First, the 
BODE cohort differs from the population assessed for LTx 
listing. In particular, the BODE cohort was not limited to 
patients aged less than 65 years, which is usually a criterion 
for LTx. Furthermore, active smokers were not excluded 
from the BODE cohort, while sustained smoking cessation 
is required for LTx.3,10 In addition, the original BODE cohort 
included only 7% women.15
As FEV
1
 does not describe the full picture of pulmonary 
function alterations in COPD, there is also a rationale to 
assess other lung function parameters for the prediction of 
survival. In particular, the diffusing capacity of the lungs for 
carbon monoxide (DL,CO; also known as the carbon mon-
oxide transfer factor) has been shown to be an independent 
predictor of survival.16
Accordingly, the aims of the present study were to test 
whether age, smoking status, gender and DL,CO added to 
the BODE score for the prediction of survival in COPD in 
a cohort of patients with a large disease severity scatter. 
In a second step, as age indeed added to the BODE score, 
we were interested in assessing the value of the BODE as 
well as other potential parameters for predicting survival at 
5 years in patients aged less than 65 years, since this is the 
age limit generally considered for LTx.12
Methods
This was a retrospective cohort study of COPD patients with 
a prospective BODE score assessment.
study population
Files of patients with a BODE assessment at the outpatient 
COPD clinic of the CHU-UCL-Namur (Site Godinne) were 
retrospectively retrieved. The CHU-UCL-Namur is a tertiary 
care hospital with an LTx program. Inclusion in the study 
required a history of smoking (.10 pack-years) and a clinical 
diagnosis of COPD confirmed by spirometry according to 
the modified GOLD criteria (post-bronchodilator FEV
1
/FVC 
below the lower limit of normal).
The files of 487 consecutive patients with a BODE 
assessment were reviewed. Patients were excluded (n=18) 
if they had no smoking history, known active or recent 
(,5 years) neoplastic disease, or chronic heart failure with 
left ventricular ejection fraction ,40%, leaving 469 patients 
for the analysis.
study measurements
The BODE was prospectively assessed as a routine in the 
outpatient COPD clinic. Files of patients with a BODE 
measurement between September 2009 and May 2013 were 
reviewed. Moreover, the files of the patients were reviewed 
for gender, age, smoking status (current or ex-smoker) and 
pulmonary function test parameters at the time of BODE 
assessment, as well as for survival status. If data were avail-
able for the BODE score calculation before September 2009, 
the BODE score was calculated at that time, which was used 
as study inclusion. Spirometry and gas transfer were mea-
sured using a HypAir System (Medisoft, Sorinnes, Belgium). 
Quality control followed accepted guidelines, with DL,CO gas 
analyzer calibrations being carried out prior to each session 
and volume calibrations daily. Owing to the retrospective 
nature of the data analysis, DL,CO was missing at the time of 
BODE assessment in 33 patients. Predicted values are those 
of the European Coal and Steel Community.17 The Six-Minute 
Walk Test was performed according to guidelines.18
Patients were censored at the time of last contact or LTx 
for the survival analysis. Survival status was determined up 
to May 2018 from medical files, including those of referring 
physicians, as well as from obituary websites.
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statistical analysis
Statistical analysis was performed using the NCSS software 
version 11 (NCSS, LLC, Kaysville, UT, USA) for Windows 7 
(Microsoft Corporation, Redmond, WA, USA). Data (includ-
ing percent predicted values) are presented as mean ± SD or 
absolute numbers. Differences between groups were assessed 
using an independent samples t-test, ANOVA or the chi-
squared model, where appropriate. The parameters found to 
be significantly associated with survival in univariate analysis 
were subsequently entered in a multivariate Cox proportional 
hazard regression analysis model. The BODE score, FEV
1
 and 
DL,CO were entered in the survival analysis as categorical 
variables (quartiles). The same was done for age (,65 
or $65 years). The calculated BODE IQRs were the same as 
in the study by Celli et al.10 An additional Cox proportional 
hazard regression analysis was performed with age, BODE 
score, FEV
1
 and DL,CO analyzed as continuous variables. 
The median survival was calculated using the Kaplan–Meier 
method. Determinants of survival at 5 years were assessed 
by the receiver operating characteristic (ROC) curve method. 
A transformation of the BODE was used for this analysis 
(10-BODE score) in order for lower values to be predictive of 
survival outcome. Since this analysis was intended to assess 
LTx listing criteria, it was restricted to patients aged less than 
65 years. Moreover, patients alive and censored less than 
5 years after inclusion were excluded from this analysis.
A level of P,0.05 was considered statistically significant.
The study was accepted by the ethics committee of the 
CHU-UCL-Namur (approval 149/2015). Because of the retro-
spective nature of the analysis, the ethics committee considered 
that patient consent was not required. Patient data confidential-
ity was respected at all steps of the study, which was conducted 
in accordance with the Declaration of Helsinki.
Results
The study population comprised 469 patients. The main 
characteristics at the time of BODE assessment are described 
in Table 1. There was a good representation of both genders 
and GOLD stages II–IV.
During the follow-up, 60 patients (13%) underwent LTx 
after a mean of 33 months (IQR 16–45) and were censored 
at that time for the survival analysis. Moreover, 170 (36%) 
died without LTx after a mean of 42 months (IQR 22–58). 
There were 239 patients alive without LTx at the last sur-
vival status assessment, with a mean follow-up of 63 months 
(IQR 50–85).
Characteristics of the patients according to survival or 
LTx status are shown in Table 2. As expected, age was lower 
in survivors and patients who underwent LTx. The BODE 
was lower in survivors and higher in transplanted patients; 
the reverse was true for pulmonary function indices.
As shown in Table 3, the BODE score was strongly 
associated with survival in univariate analysis. As expected, 
FEV
1
 was also associated with survival, with the association 
being stronger when expressed as an absolute value rather 
than percent predicted. Moreover, age and DL,CO were 
also strongly associated with survival in univariate analysis. 
However, there was no significant association with smoking 
status or gender.
As FEV
1
 is one component of the BODE, it was not 
included in the multivariate model. The multivariate analysis 
showed that age and DL,CO (both expressed as categorical 
variables) were predictors of survival, independent of the 
BODE score.
A Cox regression model including the BODE score, age 
and DL,CO as continuous variables confirmed that these 
parameters were strongly and independently related to 
survival (all P-values ,0.001).
Survival was significantly better for patients aged less than 
65 years in each BODE quartile (Table 4, Figure 1) except for 
the second quartile, where the same tendency was observed 
without reaching statistical significance. Median survival for 
patients younger than 65 years in the BODE fourth quartile 
(n=63) was 55 months (95% CI 40–65 months); this outcome 
was very similar (55 months; 95% CI 40–59 months) when 
active smokers at the time of BODE assessment (n=9) were 
excluded from this subgroup analysis.
As can be seen from Table 5 and Figure 2, the ROC 
analysis for the prediction of survival status at 5 years showed 
similar areas under the curve (AUCs) for the BODE score, 
Table 1 Patient characteristics at the time of BODe assessment
n 469
gender (F/M) 179/290
age (years) 63±9
Current/ex-smokers 145/324
Post-BD FeV1 (l) 1.22±0.62
Post-BD FeV1 (%) 45±20
Post-BD FeV1/FVC 0.44±0.13
Dl,CO (%)a 47±24
gOlD stage (I–IV) 25/150/163/131
BODe 4.0±2.4
BODe quartile (1–4) 139/129/119/82
Notes: Data are presented as absolute numbers or mean ± sD. an=436.
Abbreviations: BD, bronchodilator; BODE, body mass index, airflow obstruction, 
dyspnea and exercise capacity; Dl,CO, diffusing capacity of the lungs for carbon 
monoxide; F, female; M, male; %, percent predicted.
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FEV
1
 (whether expressed as absolute values or percent 
predicted) and DL,CO. There were no significant differences 
between these predictors of survival at 5 years, although the 
difference between the AUCs for the BODE and FEV
1
 (L) 
tended to favor the former (P=0.051).
Discussion
In this large cohort of 469 COPD patients with a good rep-
resentation of moderate to very severe disease and both 
genders, we found that age and DL,CO significantly and inde-
pendently added to the BODE for the prediction of survival.
To our knowledge, only two studies have previously 
tested the added value of age to the BODE for the predic-
tion of survival in COPD. From the data gathered from the 
medical therapy arm of the National Emphysema Treat-
ment Trial (NETT), Martinez et al identified several factors 
associated with an increased mortality. They showed that 
older age, but also lowered DL,CO and higher residual vol-
ume, significantly added to the BODE to predict survival.19 
By design, the NETT was restricted to very selected patients 
with severe or very severe COPD and the BODE score was 
a proxy since dyspnea was assessed by the University of 
California San Diego Shortness of Breath Questionnaire 
rather than by the mMRC scale. Our results extend these 
findings to a broader range of COPD severity. In contrast, 
Casanova et al did not find any independent effect of age on 
top of the BODE in a cohort of patients with mostly severe 
to very severe COPD.20
As age was an independent predictor of survival in the 
present study as well as in the NETT cohort, this suggests 
that relying on survival data from the BODE cohort may 
overestimate the survival advantage of LTx when listing 
patients on the BODE criterion. In the present cohort, 
survival was significantly better in patients aged less than 
65 years for each BODE quartile except for the second, where 
we also observed a strong tendency for better survival in 
younger patients. This extends the findings of Reed et al,15 
who analyzed the survival of patients in the fourth quartile 
Table 2 Patient characteristics at baseline according to survival or transplantation status
 Survived Died Transplanted P-value
n 239 170 60  
gender (F/M) 91/148 58/112 30/30 0.09
age (years) 62±9 66±10 57±5 ,0.0001
Current/ex-smokers 90/149 50/120 5/55 ,0.0001
BODe 2.9±2.0 4.7±2.3 6.3±1.4 ,0.0001
BODe quartile (1–4) 111/77/37/14 28/47/54/41 0/5/28/27 ,0.0001
Post-BD FeV1 (l) 1.45±0.64 1.08±0.53 0.66±0.21 ,0.0001
Post-BD FeV1 (%) 53±19 41±17 24±7 ,0.0001
Post-BD FeV1/FVC 0.48±0.12 0.43±0.12 0.30±0.07 ,0.0001
Dl,CO (%) 56±23 41±22 27±12 ,0.0001
Note: Data are presented as absolute numbers or mean ± sD.
Abbreviations: BD, bronchodilator; BODE, body mass index, airflow obstruction, dyspnea and exercise capacity; DL,CO, diffusing capacity of the lungs for carbon monoxide; 
F, female; M, male; %, percent predicted.
Table 3 Univariate and multivariate Cox regression models for survival analysis
 
 
Univariate analysis Multivariate analysis
RR 95% CI P-value RR 95% CI P-value
age ($65 vs ,65 years) 1.62 1.20–2.19 0.0017 1.92 1.39–2.66 0.0001
BODe (4th vs 1st–3rd quartiles) 3.24 2.25–4.65 ,0.001 2.52 1.61–3.94 0.0001
Dl,CO (%) (1st vs 2nd–4th quartiles) 3.33 2.34–4.75 ,0.001 2.75 1.84–4.1 ,0.0001
FeV1 (l) (1st vs 2nd–4th quartiles) 2.94 2.12–4.09 ,0.001    
FeV1 (%) (1st vs 2nd–4th quartiles) 1.85 1.31–2.62 =0.001    
gender (M vs F) 1.12 0.82–1.54 0.47    
smoker (current vs ex) 1.15 0.83–1.6 0.40    
Abbreviations: BODE, body mass index, airflow obstruction, dyspnea and exercise capacity; DL,CO, diffusing capacity of the lungs for carbon monoxide; F, female; M, male; 
%, percent predicted; rr, risk ratio for death.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
8.
48
.7
7.
18
1 
on
 1
5-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3967
Prediction of survival in COPD
of BODE listed for LTx in the United Network of Organ 
Sharing (UNOS) database. These patients had a significantly 
better survival than the patients in the BODE fourth quartile 
from the original cohort of Celli et al.10 In the present study, 
the median survival of patients aged less than 65 years in 
the BODE fourth quartile was 55 months. This contrasts 
with the median survival of 37 months in the BODE vali-
dation cohort,10 but fits very well with the median survival 
of 59 months observed in the UNOS cohort of patients 
listed for LTx with a BODE score in the fourth quartile.15 
Table 4 survival difference according to BODe quartile and age
Age ,65 years Age $65 years HR for death 
(,65 vs $ 65 years)
P-value
n Median survival 
(months)
n Median survival 
(months)
BODe Q1 75  62  0.31 (0.15–0.66) 0.004
BODe Q2 71  58 80 (62–132) 0.65 (0.36–1.15) 0.13
BODe Q3 81 67.5 (56–71) 33 51 (38–58) 0.45 (0.24–0.82) 0.002
BODe Q4 63 55 (40–65) 19 38 (13–42) 0.44 (0.21–0.92) 0.008
Abbreviations: BODE, body mass index, airflow obstruction, dyspnea and exercise capacity; Q1–4, quartiles 1–4.
Figure 1 Kaplan–Meier survival curves in BODe quartiles 1 (A), 2 (B), 3 (C) and 4 (D) in patients aged ,65 years (continuous lines) or $65 years (dotted lines).
Abbreviation: BODE, body mass index, airflow obstruction, dyspnea and exercise capacity.
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A limitation of the UNOS database study is the absence of 
dyspnea assessment by the mMRC score.
Altogether, these results strongly suggest that using the 
BODE score in the LTx selection process for COPD should 
rely on data retrieved from cohorts of patients younger than 
65 years. Fortunately, even if the survival benefit of LTx is 
overestimated when using data from the BODE cohort, our 
data and those of the UNOS database still suggest a survival 
benefit in the fourth quartile of BODE in patients aged less 
than 65 years. Indeed, according to data from the ISHLT 
registry, the median survival after adult LTx is 6 years,12 and 
5.8 years in those transplanted for COPD.4
Some programs now offer LTx for patients aged up to 
70 years, or even more. However, these patients are more 
likely to be denied LTx in the presence of relative contraindi-
cations than younger patients. Accordingly, a comparison of 
survival with a population selected according to the absence 
of absolute contraindication for LTx, as in the present study, 
would be of doubtful significance.
As FEV
1
 addresses only some aspects of the functional 
derangements of the respiratory system associated with 
COPD, there is a rationale to assess the relationship between 
survival and other respiratory function parameters. We 
found that DL,CO significantly added to the BODE index 
to predict survival. This is in line with the results of Boutou 
et al,16 who showed that DL,CO was the only functional 
parameter related to mortality in a multivariate analysis. Of 
note, FEV
1
 was not independently related to survival in this 
cohort, but this may be due to the fact that the majority of the 
included patients had very severe airway obstruction (GOLD 
stage IV).16 Few other studies have assessed the association 
between DL,CO and survival in patients with COPD, but 
two such studies confirmed an independent association with 
survival.19,21 Our data extend these findings by showing that 
DL,CO adds to the BODE to predict survival in a cohort with 
a larger spectrum of disease severity.
As the median survival after adult LTx is 6 years,12 we 
looked at the ability of different parameters to predict survival 
at 5 years in patients aged less than 65 years using ROC 
curve analysis. The highest AUC values were observed for 
the BODE score as well as FEV
1
 (% predicted). However, 
no significant difference was observed between the AUC 
for FEV
1
 (whether expressed as absolute value or percent 
predicted), DL,CO or the BODE score. The AUC of all 
these parameters could be considered as acceptable for the 
discrimination of surviving patients at 5 years.22 However, 
with the highest value at 0.78, there is room for improvement. 
This would require studying a larger population of COPD 
patients aged less than 65 years without severe comorbidity, 
and combining the BODE with other parameters of interest 
such as DL,CO.
Our study has several strengths and limitations. It 
includes a large population with a diversity of airflow 
obstruction severity and a long follow-up. This is a single-
center cohort from a tertiary care hospital. This may limit 
the generalizability of the results. The retrospective nature 
of the analysis may also be viewed as a weakness. However, 
the measurements taken were a reflection of daily practice, 
and the primary endpoint of the study (all-cause mortality) 
is robust and unlikely to be subject to bias.
Conclusion
In a large cohort of COPD patients, we found that increased 
age and lowered DL,CO, but neither smoking status nor 
gender, added to the BODE to predict survival. The data from 
Table 5 rOC curve analysis for predicting survival status at 
5 years in patients aged ,65 years (n=149)
Parameter AUC (95% CI)
Post-BD FeV1 (l) 0.73 (0.63–0.81)
Post-BD FeV1 (%) 0.76 (0.67–0.83)
Dl,CO (%) 0.75 (0.65–0.83)
BODe 0.78 (0.69–0.85)
Abbreviations: aUC, area under the curve; BD, bronchodilator; BODe, body 
mass index, airflow obstruction, dyspnea and exercise capacity; DL,CO, diffusing 
capacity of the lungs for carbon monoxide; %, percent predicted; rOC, receiver 
operating characteristic.
Figure 2 rOC curve analysis for the prediction of death at 5 years according to 
BODe score, FeV1 (l) or Dl,CO (% predicted).
Abbreviations: BODE, body mass index, airflow obstruction, dyspnea and exercise 
capacity; Dl,CO, diffusing capacity of the lungs for carbon monoxide; rOC, receiver 
operating characteristic.
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the original BODE cohort underestimate mortality when used 
in candidates for LTx. A BODE score $7, however, remains 
an acceptable criterion for listing patients on the waiting list. 
Testing other multidimensional indices in patients younger 
than 65 years with no severe comorbidities deserves more 
studies to improve the selection process for LTx in patients 
with COPD.
Abbreviations
AUC, area under the curve; BMI, body mass index; BODE, 
body mass index, airflow obstruction, dyspnea and exercise 
capacity; DL,CO, diffusing capacity of the lungs for carbon 
monoxide; ISHLT, International Society for Heart and Lung 
Transplantation; LTx, lung transplantation; NETT, National 
Emphysema Treatment Trial; ROC, receiver operating 
characteristic; UNOS, United Network of Organ Sharing.
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